These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 1973947)

  • 21. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH; Starr MS
    Neuroscience; 1987 Dec; 23(3):1001-10. PubMed ID: 2963970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of locally applied D1 and D2 agonists on striatal neurons with 6-OHDA and pertussis toxin lesions.
    Strömberg I; Bickford-Wimer P
    Brain Res; 1991 Nov; 564(2):279-85. PubMed ID: 1687374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity.
    LaHoste GJ; Yu J; Marshall JF
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7451-5. PubMed ID: 8102797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment.
    Joyce JN
    Exp Neurol; 1991 Sep; 113(3):277-90. PubMed ID: 1833220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
    Engber TM; Marin C; Susel Z; Chase TN
    Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Localization of nigrostriatal dopamine receptor subtypes and adenylate cyclase.
    Filloux F; Dawson TM; Wamsley JK
    Brain Res Bull; 1988 Apr; 20(4):447-59. PubMed ID: 3135077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.
    Jiang HK; McGinty JF; Hong JS
    Brain Res; 1990 Jan; 507(1):57-64. PubMed ID: 1967976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of the acoustic startle response by dopamine agonists after 6-hydroxydopamine lesions of the substantia nigra pars compacta: corresponding changes in c-Fos expression in the caudate-putamen.
    Meloni EG; Davis M
    Brain Res; 2000 Oct; 879(1-2):93-104. PubMed ID: 11011010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
    Paul ML; Graybiel AM; David JC; Robertson HA
    J Neurosci; 1992 Oct; 12(10):3729-42. PubMed ID: 1357113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of dopamine D-1 and D-2 receptor subtype agonists on nigrostriatal opioid dynorphin and enkephalin immunostaining in 6-hydroxydopamine lesioned rats.
    Jiang HK; Wang JY
    Chin J Physiol; 1991; 34(4):413-25. PubMed ID: 1687937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different roles of D-1 and D-2 dopamine receptors involved in locomotor activity of supersensitive mice.
    Rubinstein M; Gershanik O; Stefano FJ
    Eur J Pharmacol; 1988 Apr; 148(3):419-26. PubMed ID: 2968273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model.
    Lawler CP; Gilmore JH; Watts VJ; Walker QD; Southerland SB; Cook LL; Mathis CA; Mailman RB
    Synapse; 1995 Dec; 21(4):299-311. PubMed ID: 8869160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haloperidol and clozapine: differential effects on the sensitivity of caudate-putamen neurons to dopamine agonists and cholecystokinin following one month continuous treatment.
    Hu XT; Wang RY
    Brain Res; 1989 May; 486(2):325-33. PubMed ID: 2786442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice.
    Svensson A; Carlsson A; Carlsson ML
    J Neural Transm Gen Sect; 1992; 90(3):199-217. PubMed ID: 1363051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of a 35 kDa fos-related antigen (FRA) in the long-term induction of striatal dynorphin expression in the 6-hydroxydopamine lesioned rat.
    Bronstein DM; Ye H; Pennypacker KR; Hudson PM; Hong JS
    Brain Res Mol Brain Res; 1994 May; 23(3):191-203. PubMed ID: 7914658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of dopaminergic receptor subtypes in straub tail behaviour in mice.
    Zarrindast MR; Bayat A; Shafaghi B
    Gen Pharmacol; 1993 Jan; 24(1):127-30. PubMed ID: 8097737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
    Huang KX; Bergstrom DA; Ruskin DN; Walters JR
    Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neonatal 6-OHDA lesions differentially affect striatal D1 and D2 receptors.
    Neal BS; Joyce JN
    Synapse; 1992 May; 11(1):35-46. PubMed ID: 1351321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior.
    Sivam SP
    Brain Res; 1989 Oct; 500(1-2):119-30. PubMed ID: 2481560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Priming of D1-dopamine receptor responses: long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats.
    Criswell H; Mueller RA; Breese GR
    J Neurosci; 1989 Jan; 9(1):125-33. PubMed ID: 2521511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.